News | Coronavirus (COVID-19) | August 04, 2020

ACR to Provide Image Coordination for National COVID-19 Observational Study

The CORAL Study will help researchers describe the clinical characteristics, treatments, biology, and outcomes of hospitalized patients with COVID-19

The CORAL Study will help researchers describe the clinical characteristics, treatments, biology, and outcomes of hospitalized patients with COVID-19

Getty Images

August 4, 2020 — The American College of Radiology (ACR) Center for Research and Innovation (CRI) will serve as the imaging coordination center for the multicenter COVID-19 Observational Study (CORAL) led by Catherine "Terri" L. Hough, M.D., of the Oregon Health & Science University. The CORAL Study is part of the Prevention & Early Treatment of Acute Lung Injury (PETAL) Network, a consortium of academic and affiliated hospitals across the United States – funded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health – to conduct clinical trials in patients with or at risk for critical illness, including acute respiratory distress syndrome.

The purpose of CORAL is to inform epidemiology and resource utilization through three interrelated approaches: a registry; a detailed cohort, including a bio-specimen collection correlated with clinical phenotyping and outcomes; and a health system assessment. In collaboration with CORAL leadership, and following standards developed for this study, the ACR CRI will collect imaging exams on registry subjects, create a link between the images and clinical data collected by PETAL, archive images throughout study duration and, once complete, make images accessible to researchers.

At present, little is known about the epidemiology of novel coronavirus (COVID-19) in the United States. Rapid expansion of cases across this country and others necessitates urgent study of severe acute COVID-19 in order to care for patients, inform and develop treatments, target therapeutics, prognosticate and understand health system impacts. The CORAL Study is a responsive effort to these needs.

“We at the ACR are pleased and proud to be part of the effort by our colleagues who are caring for patients suffering with COVID-19 who require hospital care. We hope the collection of imaging and clinical data that the PETAL project creates will lead to improved treatment and diagnosis of COVID-19 complications, including advanced lung disease, stroke and cardiac dysfunction,” said Etta Pisano, M.D., chief research officer of the ACR.

Learn more about CORAL and opportunities for collaboration.

Learn more about PETAL Network.

Related Content

Newly released study results present a strong case for lung cancer screening in New Zealand — particularly for Māori whose mortality rates are between three and four times higher than other ethnic groups.

Image courtesy of Siemens Healthineers

News | Lung Imaging | September 30, 2020
September 30, 2020 — Newly released study results present a strong case for...
The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

Feature | Artificial Intelligence | September 29, 2020 | Joe Fornadel, J.D., and Wes Moran, J.D.
The number of Federal Drug Administration (FDA)-approved AI-based algorithms is significant and has grown at a steady
The FDA Center for Devices and Radiological Health's COVID-19 response by the numbers between January 1 and September 18, 2020.

The FDA Center for Devices and Radiological Health's COVID-19 response by the numbers between January 1 and September 18, 2020. Graphic courtesy of FDA

News | Coronavirus (COVID-19) | September 29, 2020
September 29, 2020 — On September 28, FDA Commissioner of Food and Drugs...
Lung and respiratory health pioneer paves way for more precise care of complex respiratory conditions
News | Artificial Intelligence | September 25, 2020
September 25, 2020 — VIDA Diagnostics, Inc. announced that it has received 510(k) clearance from the Food and Drug Ad
RADLogics AI-Powered solution in use: chest X-ray of COVID-19 positive case with heatmap key image.

RADLogics AI-Powered solution in use: chest X-ray of COVID-19 positive case with heatmap key image.

News | Artificial Intelligence | September 23, 2020
September 23, 2020 — RADLogics